Journal ArticleDOI
Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?
Elena Geuna,Andrea Milani,Stefania Redana,Valentina Rossi,Giorgio Valabrega,Massimo Aglietta,Filippo Montemurro +6 more
TLDR
Most of the studies using biological agents to hit multiple targets in HER2-positive breast cancer patients confirm that resistance to single-agent Her2-targeting can be overcome and it is possible that newer molecular predictive factors may allow a more rationale choice of the most appropriate targeting for each individual patient.Abstract:
Introduction: Pharmacological targeting of the tyrosine kinase receptor HER2 with the monoclonal antibody trastuzumab has dramatically changed the outlook of HER2-positive breast cancer patients. However, HER2 is part of a more complex biological network that, when deregulated, plays a central role in sustaining the cancer phenotype. These interactions account for primary or acquired resistance to drugs that hit a single biological target, like trastuzumab. Several preclinical models suggest that simultaneous targeting of crucial metabolic pathways has the potential to circumvent or delay the onset of resistance phenomena in HER2-positive breast cancer cells. Areas covered: This review describes the rationale and results of clinical trials using biologically targeted agents in HER2-positive breast cancer patients. Single drugs that hit multiple targets and cocktails of biologically targeted agents are considered, whereas combinations with chemotherapy are not addressed. Expert opinion: Most of the studies...read more
Citations
More filters
Journal Article
Novel mechanisms of glucocorticoid resistance in childhood acute lymphoblastic leukemia.
TL;DR: It is reported that PTEN activation contributes to trastuzumab's antitumor activity and PTEN deficiency is a powerful predictor for trastzumab resistance, suggesting that PI3K-targeting therapies could overcome this resistance.
Journal ArticleDOI
Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles.
Wei Li,He Zhao,Weizhu Qian,Huafei Li,Li Zhang,Zengwei Ye,Ge Zhang,Mao Xia,Jinfeng Li,Jie Gao,Bohua Li,Geng Kou,Jianxin Dai,Hao Wang,Yajun Guo +14 more
TL;DR: Due to the high stability and super-targeting, the in vivo xenografted gastric tumor growth was significantly inhibited with relative tumor volume <2 which was much smaller than ≈ 5 of the control.
Journal ArticleDOI
The role of pazopanib on tumour angiogenesis and in the management of cancers: A review.
Dinesh Kumar Chellappan,Jestin Chellian,Zhao Yin Ng,Yan Jinn Sim,Chiu Wei Theng,Joyce Ling,Mei Wong,Jia Hui Foo,Goh Jun Yang,Li Yu Hang,Saranyah Shanmugah Nathan,Yogendra Singh,Gaurav Gupta +12 more
TL;DR: The results obtained can provide a decent reference when considering treatment options for angiogenesis-related malignancies and could provide newer insights leading to the future development of drugs of the same mechanism with increased efficiency and reduced adverse effects.
Journal ArticleDOI
Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer
TL;DR: Tastuzumab plus chemotherapy is the current standard of care for the upfront treatment of HER-2(+) breast cancer patients, though other anti-HER-2-targeting agents may appear as new standards in the upcoming years.
Journal ArticleDOI
Tetraspecific ligand for tumor-targeted delivery of nanomaterials.
TL;DR: The results demonstrate that the tetraspecific ligand, through multivalency and synergistic binding, can be readily used to generate various 'smart' biomaterials with greatly broadened tumor targeting range for simultaneous targeting of multiple signaling pathways on many different cancer types.
References
More filters
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
Cell signaling by receptor-tyrosine kinases
TL;DR: Understanding of the complex signaling networks downstream from RTKs and how alterations in these networks are translated into cellular responses provides an important context for therapeutically countering the effects of pathogenic RTK mutations in cancer and other diseases.
Journal ArticleDOI
Untangling the ErbB signalling network
Yosef Yarden,Mark X. Sliwkowski +1 more
TL;DR: When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion.
Journal ArticleDOI
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
Edward H. Romond,Edith A. Perez,John Bryant,Vera J. Suman,Charles E. Geyer,Nancy E. Davidson,Elizabeth Tan-Chiu,Silvana Martino,Soonmyung Paik,Peter A. Kaufman,Sandra M. Swain,Thomas M. Pisansky,Louis Fehrenbacher,Leila A. Kutteh,Victor G. Vogel,Daniel W. Visscher,Greg Yothers,Robert B. Jenkins,Ann M. Brown,S. R. Dakhil,Eleftherios P. Mamounas,Wilma L. Lingle,Pamela M. Klein,James N. Ingle,Norman Wolmark +24 more
TL;DR: Tastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer.